Forte Biosciences (FBRX) Profit After Tax (QoQ) (2016 - 2026)
Forte Biosciences (FBRX) Profit After Tax (QoQ) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn |
| 10 | Forte Biosciences | 1.36 Bn | 1.31 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.64% |
| Dec 31, 2025 | -40.09% |
| Sep 30, 2025 | -57.19% |
| Jun 30, 2025 | 28.15% |
| Mar 31, 2025 | -118.90% |
| Dec 31, 2024 | 14.78% |
| Sep 30, 2024 | 32.92% |
| Jun 30, 2024 | -68.61% |
| Mar 31, 2024 | -26.36% |
| Dec 31, 2023 | 41.05% |
| Sep 30, 2023 | -11.97% |
| Jun 30, 2023 | -31.73% |
| Mar 31, 2023 | -38.47% |
| Dec 31, 2022 | -43.44% |
| Sep 30, 2022 | -12.03% |
| Jun 30, 2022 | -18.23% |
| Mar 31, 2022 | 23.17% |
| Dec 31, 2021 | 56.90% |
| Sep 30, 2021 | -33.36% |
| Jun 30, 2021 | -20.98% |